PDF herunterladen
Semin Thromb Hemost 2019; 45(02): 141-149
DOI: 10.1055/s-0038-1661387
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Risk of Recurrent Venous Thromboembolism in Autoimmune Diseases: A Systematic Review of the Literature

Jaime Francisco Borjas-Howard
1   Division of Hemostasis and Thrombosis, Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
,
Karina de Leeuw
2   Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
,
Abraham Rutgers
2   Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
,
Karina Meijer
1   Division of Hemostasis and Thrombosis, Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
,
Vladimir Ynse Ieuwe Gerardus Tichelaar
1   Division of Hemostasis and Thrombosis, Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
3   Department of Vascular Medicine, Department of Internal Medicine, Amsterdam Medical Center, University of Amsterdam, Amsterdam, The Netherlands
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
28. Juni 2018 (online)

    Lizenzen und Reprints

Abstract

Despite an abundance of literature on the risk of a first venous thromboembolic event (VTE) in autoimmune diseases, specific recommendations about managing VTE in autoimmune diseases are lacking. This article aimed to collect evidence on the risk of recurrent VTE in patients with autoimmune diseases. The authors searched PubMed/Embase for studies including patients with VTE and autoimmune diseases as an exposure or studies including patients with autoimmune diseases in which recurrent VTE was one of the outcomes. Eleven articles were selected from 4,739 unique abstracts. Of the 11 studies, 3 reported time-dependent rates. Two studies collected rates of recurrence in Behcet's disease, reporting a 5-year recurrence risk between 35 and 40%. However, the 5-year recurrence risk was lower than 10% in patients treated with immunosuppressant medication, while two studies suggested frequent recurrence in patients on only anticoagulant therapy. The other study reporting time-dependent incidence concerned patients with inflammatory bowel disease and index VTE. The 5-year risk of recurrent VTE was 33.4%, yielding a hazard ratio of 1.7 versus controls. All studies were retrospective and therefore risk may overestimate recurrence risk in comparison with known prospective cohort studies. There are insufficient data to make confident recommendations about the management of recurrent VTE prevention in patients with autoimmune diseases in general. The overall VTE risk profile, lower effectiveness of anticoagulants, and the observation that immunosuppression lowered risk of recurrence in patients with Behcet's disease seem to warrant immunosuppressant therapy over anticoagulation as a first consideration when preventing VTE recurrence in these patients.

Keywords

venous thromboembolism - autoimmune disease - rheumatoid arthritis - risk

Addendum

J.F.B-H. was responsible for the study idea and design, performed the literature search and review, and wrote the manuscript. K.d.L. was responsible for study design, performed literature search and review, and reviewed the manuscript. A.R. was responsible for study design and reviewed the manuscript. K.M. was responsible for study idea and design, supervised writing of the manuscript, and reviewed the manuscript. Y.I.G.V.T. was responsible for study idea and supervision of manuscript writing process and reviewed the manuscript.


 

  • References

  • 1 Carruthers EC, Choi HK, Sayre EC, Aviña-Zubieta JA. Risk of deep venous thrombosis and pulmonary embolism in individuals with polymyositis and dermatomyositis: a general population-based study. Ann Rheum Dis 2016; 75 (01) 110-116
    CrossrefPubMedGoogle Scholar
  • 2 Chung WS, Lin CL, Chang SN, Lu CC, Kao CH. Systemic lupus erythematosus increases the risks of deep vein thrombosis and pulmonary embolism: a nationwide cohort study. J Thromb Haemost 2014; 12 (04) 452-458
    CrossrefPubMedGoogle Scholar
  • 3 Peeters PJ, Bazelier MT, Uitdehaag BM, Leufkens HG, De Bruin ML, de Vries F. The risk of venous thromboembolism in patients with multiple sclerosis: the Clinical Practice Research Datalink. J Thromb Haemost 2014; 12 (04) 444-451
    CrossrefPubMedGoogle Scholar
  • 4 Selva-O'Callaghan A, Fernández-Luque A, Martínez-Gómez X, Labirua-Iturburu A, Vilardell-Tarrés M. Venous thromboembolism in patients with dermatomyositis and polymyositis. Clin Exp Rheumatol 2011; 29 (05) 846-849
    PubMedGoogle Scholar
  • 5 Ungprasert P, Sanguankeo A. Risk of venous thromboembolism in patients with idiopathic inflammatory myositis: a systematic review and meta-analysis. Rheumatol Int 2014; 34 (10) 1455-1458
    CrossrefPubMedGoogle Scholar
  • 6 Ungprasert P, Sanguankeo A, Upala S, Suksaranjit P. Psoriasis and risk of venous thromboembolism: a systematic review and meta-analysis. QJM 2014; 107 (10) 793-797
    CrossrefPubMedGoogle Scholar
  • 7 Ungprasert P, Srivali N, Kittanamongkolchai W. Risk of venous thromboembolism in patients with Sjögren's syndrome: a systematic review and meta-analysis. Clin Exp Rheumatol 2015; 33 (05) 746-750
    PubMedGoogle Scholar
  • 8 Ungprasert P, Srivali N, Kittanamongkolchai W. Systemic sclerosis and risk of venous thromboembolism: a systematic review and meta-analysis. Mod Rheumatol 2015; 25 (06) 893-897
    CrossrefPubMedGoogle Scholar
  • 9 Ungprasert P, Srivali N, Spanuchart I, Thongprayoon C, Knight EL. Risk of venous thromboembolism in patients with rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol 2014; 33 (03) 297-304
    CrossrefPubMedGoogle Scholar
  • 10 Ungprasert P, Srivali N, Wijarnpreecha K, Thongprayoon C. Sarcoidosis and risk of venous thromboembolism: a systematic review and meta-analysis. Sarcoidosis Vasc Diffuse Lung Dis 2015; 32 (03) 182-187
    PubMedGoogle Scholar
  • 11 Ungprasert P, Tanratana P, Srivali N. Autoimmune hemolytic anemia and venous thromboembolism: a systematic review and meta-analysis. Thromb Res 2015; 136 (05) 1013-1017
    CrossrefPubMedGoogle Scholar
  • 12 Ungprasert P, Wijarnpreecha K, Tanratana P. Risk of venous thromboembolism in patients with celiac disease: a systematic review and meta-analysis. J Gastroenterol Hepatol 2016; 31 (07) 1240-1245
    CrossrefPubMedGoogle Scholar
  • 13 Tichelaar YI, Kluin-Nelemans HJ, Meijer K. Infections and inflammatory diseases as risk factors for venous thrombosis. A systematic review. Thromb Haemost 2012; 107 (05) 827-837
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 14 Zöller B, Li X, Sundquist J, Sundquist K. Autoimmune diseases and venous thromboembolism: a review of the literature. Am J Cardiovasc Dis 2012; 2 (03) 171-183
    PubMedGoogle Scholar
  • 15 Zöller B, Li X, Sundquist J, Sundquist K. Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden. Lancet 2012; 379 (9812): 244-249
    CrossrefPubMedGoogle Scholar
  • 16 Aviña-Zubieta JA, Bhole VM, Amiri N, Sayre EC, Choi HK. The risk of deep venous thrombosis and pulmonary embolism in giant cell arteritis: a general population-based study. Ann Rheum Dis 2016; 75 (01) 148-154
    CrossrefPubMedGoogle Scholar
  • 17 Aviña-Zubieta JA, Vostretsova K, De Vera MA, Sayre EC, Choi HK. The risk of pulmonary embolism and deep venous thrombosis in systemic lupus erythematosus: a general population-based study. Semin Arthritis Rheum 2015; 45 (02) 195-201
    CrossrefPubMedGoogle Scholar
  • 18 Choi HK, Rho Y-H, Zhu Y, Cea-Soriano L, Aviña-Zubieta JA, Zhang Y. The risk of pulmonary embolism and deep vein thrombosis in rheumatoid arthritis: a UK population-based outpatient cohort study. Ann Rheum Dis 2013; 72 (07) 1182-1187
    CrossrefPubMedGoogle Scholar
  • 19 Lee JJ, Pope JE. A meta-analysis of the risk of venous thromboembolism in inflammatory rheumatic diseases. Arthritis Res Ther 2014; 16 (05) 435
    CrossrefPubMedGoogle Scholar
  • 20 Schoenfeld SR, Choi HK, Sayre EC, Aviña-Zubieta JA. Risk of pulmonary embolism and deep venous thrombosis in systemic sclerosis: a general population-based study. Arthritis Care Res (Hoboken) 2016; 68 (02) 246-253
    PubMedGoogle Scholar
  • 21 Murthy SK, Nguyen GC. Venous thromboembolism in inflammatory bowel disease: an epidemiological review. Am J Gastroenterol 2011; 106 (04) 713-718
    CrossrefPubMedGoogle Scholar
  • 22 Garcia D, Akl EA, Carr R, Kearon C. Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review. Blood 2013; 122 (05) 817-824
    CrossrefPubMedGoogle Scholar
  • 23 Kearon C, Akl EA, Ornelas J. , et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 2016; 149 (02) 315-352
    CrossrefPubMedGoogle Scholar
  • 24 Lyman GH, Bohlke K, Khorana AA. , et al; American Society of Clinical Oncology. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline update 2014. J Clin Oncol 2015; 33 (06) 654-656
    CrossrefPubMedGoogle Scholar
  • 25 Lee AY, Levine MN, Baker RI. , et al; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349 (02) 146-153
    CrossrefPubMedGoogle Scholar
  • 26 Lee AY, Kamphuisen PW, Meyer G. , et al; CATCH Investigators. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA 2015; 314 (07) 677-686
    CrossrefPubMedGoogle Scholar
  • 27 van der Hulle T, den Exter PL, van den Hoven P. , et al. Cohort study on the management of cancer-associated venous thromboembolism aimed at the safety of stopping anticoagulant therapy in patients cured of cancer. Chest 2016; 149 (05) 1245-1251
    CrossrefPubMedGoogle Scholar
  • 28 Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999; 353 (9159): 1167-1173
    CrossrefPubMedGoogle Scholar
  • 29 Gladman DD, Urowitz MB. Venous syndromes and pulmonary embolism in systemic lupus erythematosus. Ann Rheum Dis 1980; 39 (04) 340-343
    CrossrefPubMedGoogle Scholar
  • 30 Alarcón-Segovia D, Delezé M, Oria CV. , et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine (Baltimore) 1989; 68 (06) 353-365
    PubMedGoogle Scholar
  • 31 Ren W, Li Z, Fu Z, Fu Q. Analysis of risk factors for recurrence of deep venous thrombosis in lower extremities. Med Sci Monit 2014; 20: 199-204
    CrossrefPubMedGoogle Scholar
  • 32 Brouwer JL, Bijl M, Veeger NJ, Kluin-Nelemans HC, van der Meer J. The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus. Blood 2004; 104 (01) 143-148
    CrossrefPubMedGoogle Scholar
  • 33 Ahn JK, Lee YS, Jeon CH, Koh EM, Cha HS. Treatment of venous thrombosis associated with Behcet's disease: immunosuppressive therapy alone versus immunosuppressive therapy plus anticoagulation. Clin Rheumatol 2008; 27 (02) 201-205
    CrossrefPubMedGoogle Scholar
  • 34 Desbois AC, Wechsler B, Resche-Rigon M. , et al. Immunosuppressants reduce venous thrombosis relapse in Behçet's disease. Arthritis Rheum 2012; 64 (08) 2753-2760
    CrossrefPubMedGoogle Scholar
  • 35 Tascilar K, Melikoglu M, Ugurlu S, Sut N, Caglar E, Yazici H. Vascular involvement in Behçet's syndrome: a retrospective analysis of associations and the time course. Rheumatology (Oxford) 2014; 53 (11) 2018-2022
    CrossrefPubMedGoogle Scholar
  • 36 Yaşar NŞ, Salgür F, Cansu DÜ, Kaşifoğlu T, Korkmaz C. Combined thrombophilic factors increase the risk of recurrent thrombotic events in Behcet's disease. Clin Rheumatol 2010; 29 (12) 1367-1372
    CrossrefPubMedGoogle Scholar
  • 37 Solem CA, Loftus EV, Tremaine WJ, Sandborn WJ. Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol 2004; 99 (01) 97-101
    CrossrefPubMedGoogle Scholar
  • 38 Novacek G, Weltermann A, Sobala A. , et al. Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. Gastroenterology 2010; 139 (03) 779-787 , 787.e1
    CrossrefPubMedGoogle Scholar
  • 39 Cosmi B, Legnani C, Tosetto A. , et al; PROLONG Investigators; FCSA, Italian Federation of Anticoagulation Clinics. Comorbidities, alone and in combination with D-dimer, as risk factors for recurrence after a first episode of unprovoked venous thromboembolism in the extended follow-up of the PROLONG study. Thromb Haemost 2010; 103 (06) 1152-1160
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 40 Douketis J, Tosetto A, Marcucci M. , et al. Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis. BMJ 2011; 342: d813
    CrossrefPubMedGoogle Scholar
  • 41 Rodger MA, Scarvelis D, Kahn SR. , et al. Long-term risk of venous thrombosis after stopping anticoagulants for a first unprovoked event: a multi-national cohort. Thromb Res 2016; 143: 152-158
    CrossrefPubMedGoogle Scholar
  • 42 Ay C, Posch F, Kaider A, Zielinski C, Pabinger I. Estimating risk of venous thromboembolism in patients with cancer in the presence of competing mortality. J Thromb Haemost 2015; 13 (03) 390-397
    CrossrefPubMedGoogle Scholar
  • 43 Jennette JC, Falk RJ, Bacon PA. , et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65 (01) 1-11
    CrossrefPubMedGoogle Scholar
  • 44 Klok FA, Kooiman J, Huisman MV, Konstantinides S, Lankeit M. Predicting anticoagulant-related bleeding in patients with venous thromboembolism: a clinically oriented review. Eur Respir J 2015; 45 (01) 201-210
    CrossrefPubMedGoogle Scholar
  • 45 Schulman S, Kearon C, Kakkar AK. , et al; RE-MEDY Trial Investigators; RE-SONATE Trial Investigators. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013; 368 (08) 709-718
    CrossrefPubMedGoogle Scholar
  • 46 Eischer L, Eichinger S, Kyrle PA. The risk of recurrence in women with venous thromboembolism while using estrogens: a prospective cohort study. J Thromb Haemost 2014; 12 (05) 635-640
    CrossrefPubMedGoogle Scholar
  • 47 Davidson BL, Verheijen S, Lensing AW. , et al. Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin. JAMA Intern Med 2014; 174 (06) 947-953
    CrossrefPubMedGoogle Scholar
  • 48 Kearon C, Ageno W, Cannegieter SC, Cosmi B, Geersing GJ, Kyrle PA. ; Subcommittees on Control of Anticoagulation, and Predictive and Diagnostic Variables in Thrombotic Disease. Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH. J Thromb Haemost 2016; 14 (07) 1480-1483
    CrossrefPubMedGoogle Scholar